Clinical Trials Browser

INDUSTRY × Neoplasm Metastasis × Panitumumab × Clear all

Carcinoma, Non-Small-Cell Lung, Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT06983743 2025-09-11

AURORAS-1

Phase 1 Recruiting

200 enrolled

Tumor-Agnostic

Neoplasm Metastasis, Neoplasms

NCT00819780 2022-12-06

PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

Phase 2 Completed

285 enrolled 31 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT00089635 2022-11-07

Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer

Phase 2 Completed

203 enrolled 14 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Colorectal Neoplasms

NCT00113763 2022-11-07

Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer

Phase 3 Completed

463 enrolled 17 charts

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00446446 2022-10-05

PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)

Phase 2 Completed

52 enrolled 17 charts

Head & Neck

Carcinoma, Carcinoma, Squamous Cell, Head and Neck Neoplasms, Neoplasm Metastasis, Neoplasms

NCT01001377 2022-09-21

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

Phase 3 Completed

1,010 enrolled 22 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT00418938 2018-10-17

SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial

Phase 2 Completed

266 enrolled 17 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00454779 2018-10-17

PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response

Phase 2 Completed

113 enrolled 18 charts

Neoplasm Metastasis, Recurrence

NCT00563316 2016-04-12

Effect of Panitumumab on the Pharmacokinetics of Irinotecan

Phase 1 Completed

28 enrolled 11 charts

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Colorectal Neoplasms

NCT00411450 2016-02-15

PRECEPT

Phase 2 Completed

116 enrolled 20 charts

Gastrointestinal

Colonic Neoplasms, Neoplasm Metastasis, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00083616 2014-01-10

Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy

Phase 2 Completed

185 enrolled 15 charts

Gastrointestinal

Neoplasm Metastasis, Colorectal Neoplasms

NCT00111774 2013-05-14

Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma

Phase 2 Completed

150 enrolled

Gastrointestinal

Carcinoma, Colonic Neoplasms, Neoplasm Metastasis, Rectal Neoplasms, Colorectal Neoplasms

NCT00113776 2011-01-21

Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer

Phase 2 Completed

Gastrointestinal

Neoplasm Metastasis, Neoplasms, Rectal Neoplasms, Colorectal Neoplasms

NCT00101920 2010-10-15

ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)

Phase 2 Completed

50 enrolled

Thoracic

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis

NCT00034346 2007-12-24

ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)

Phase 2 Completed

194 enrolled

Thoracic

Carcinoma, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasm Metastasis, Neoplasms

Clinical Trials

A Study to Find a Suitable Dose of ASP5834 in Adults With Solid Tumors

AURORAS-1

PEAK: Panitumumab Plus mFOLFOX6 vs. Bevacizumab Plus mFOLFOX6 for First Line Treatment of Metastatic Colorectal Cancer (mCRC) Patients With Wild-Type Kirsten Rat Sarcoma-2 Virus (KRAS) Tumors

Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer

Evaluating Panitumumab (ABX-EGF) Plus Best Supportive Care Versus Best Supportive Care in Patients With Metastatic Colorectal Cancer

PRISM (Panitumumab Regimen In Second-line Monotherapy of Head and Neck Cancer)

ASPECCT: A Study of Panitumumab Efficacy and Safety Compared to Cetuximab in Patients With KRAS Wild-Type Metastatic Colorectal Cancer

SPIRITT - Second-Line Panitumumab Irinotecan Treatment Trial

PARTNER: Panitumumab Added to Regimen for Treatment of Head aNd Neck Cancer Evaluation of Response

Effect of Panitumumab on the Pharmacokinetics of Irinotecan

PRECEPT

Evaluating Panitumumab (ABX-EGF) Monotherapy in Patients With Metastatic Colorectal Cancer Following Treatment With Fluoropyrimidine, Irinotecan, and Oxaliplatin Chemotherapy

Evaluating ABX-EGF in Patients With Metastatic ColorectalCarcinoma

Evaluating ABX-EGF Extended Therapy in Subjects With MetastaticColorectal Cancer

ABX-EGF as Second Line Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)

ABX-EGF in Combination With Paclitaxel and Carboplatin for the Treatment of Advanced Non-Small-Cell Lung Cancer (NSCLC)